| Vertex Pharmaceuticals is engaged in developing and commercializing therapies for the treatment of cystic fibrosis (CF). Co.'s marketed medicines are SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is developing VX-150, a NaV1.8 inhibitor, as a potential treatment for pain. Co. is co-developing CTX001, an investigational gene editing treatment, for the treatment of beta-thalassemia and sickle cell disease, with CRISPR Therapeutics AG. We show 41 historical shares outstanding datapoints in our coverage of VRTX's shares outstanding history.|
Understanding the changing numbers of VRTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VRTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VRTX by allowing them to research VRTX shares outstanding history
as well as any other stock in our coverage universe.